83 Biggest Movers From Yesterday
Gainers
Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.
6 Analysts Have This to Say About Tandem Diabetes Care
Within the last quarter, Tandem Diabetes Care (NASDAQ:TNDM) has observed the following analyst ratings:
SVB Leerink Maintains Market Perform on Tandem Diabetes Care, Lowers Price Target to $110
SVB Leerink analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Market Perform and lowers the price target from $120 to $110.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Tandem Diabetes Care Highlights Data Confirming Its t:slim X2 Insulin Pump With Control-IQ Resulted In Immediate, Ongoing Improvements In Glycemic Control At International Conference on Advanced Technologies and Treatments for Diabetes
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid
Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook
Tandem Diabetes Care Inc (NASDAQ: TNDM) reported
Expert Ratings For Tandem Diabetes Care
Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $166
Wells Fargo analyst Lawrence Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and raises the price target from $160 to $166.